Literature DB >> 23021490

In vitro functional characterization of missense mutations in the LDLR gene.

S Silva1, A C Alves, D Patel, R Malhó, A K Soutar, M Bourbon.   

Abstract

BACKGROUND: Mutations in the LDL receptor gene are the major cause of familial hypercholesterolaemia (FH) but it has been previously shown that the simple finding of a variation in the coding sequence of the LDLR does not confirm that it is the actual cause of FH. The pathogenicity of five missense alterations in the LDLR gene coding sequence found in a previous epidemiologic study was investigated.
METHODS: The effects of the different sequence variants on LDLR expression and activity were analysed in vitro stably transfected CHO-ldlA7 cells by immunobloting of cell extracts, by uptake and degradation rates of (125)I-labelled LDL and immunofluorescence microscopy of whole cells. Analysis in silico was also performed.
RESULTS: LDLR functional assays showed that variants p.V429L, p.W490R and p.S648P of the LDLR coding sequence severely impaired receptor function, while variant p.P685S had a milder effect and cells carrying p.V859M variant had LDL clearance rates comparable to cells expressing normal LDLR. In silico analysis failed to predict correctly the effect of 4/5 alterations.
CONCLUSION: Assessing the pathogenicity of the different variants found in patients with clinical diagnosis of FH is of great importance to distinguish pathogenic mutations from rare silent variants and has clinical implications for determining the associated cardiovascular risk.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021490     DOI: 10.1016/j.atherosclerosis.2012.08.017

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia.

Authors:  Ana Margarida Medeiros; Ana Catarina Alves; Pedro Aguiar; Mafalda Bourbon
Journal:  J Lipid Res       Date:  2014-03-13       Impact factor: 5.922

2.  The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia.

Authors:  Asier Benito-Vicente; Ana Catarina Alves; Aitor Etxebarria; Ana Medeiros Medeiros; Cesar Martin; Mafalda Bourbon
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

3.  Functional characterization of two low-density lipoprotein receptor gene mutations in two Chinese patients with familial hypercholesterolemia.

Authors:  Haihong Wang; Shengyuan Xu; Liyuan Sun; Xiaodong Pan; Shiwei Yang; Luya Wang
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

4.  Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment.

Authors:  Aitor Etxebarria; Asier Benito-Vicente; Ana C Alves; Helena Ostolaza; Mafalda Bourbon; Cesar Martin
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

5.  LDLR C1725T Gene Polymorphism Frequency in Type 2 Diabetes Mellitus Patients With Dyslipidemia.

Authors:  Zuhal Eroglu; Ece Harman; Egemen Vardarli; Meral Kayikcioglu; Asli Tetik Vardarli
Journal:  J Clin Med Res       Date:  2016-09-29

6.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

Review 7.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

8.  Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.

Authors:  Poulabi Banerjee; Kuo-Chen Chan; Michel Tarabocchia; Asier Benito-Vicente; Ana C Alves; Kepa B Uribe; Mafalda Bourbon; Paul J Skiba; Robert Pordy; Daniel A Gipe; Daniel Gaudet; Cesar Martin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-03       Impact factor: 8.311

9.  Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.

Authors:  Joana Rita Chora; Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

10.  Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia.

Authors:  Praseetha Kizhakkedath; Anne John; Buthaina K Al-Sawafi; Lihadh Al-Gazali; Bassam R Ali
Journal:  FEBS Open Bio       Date:  2019-10-23       Impact factor: 2.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.